These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25481307)

  • 1. Polymorphic genetic variations of cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population.
    Umamaheswaran G; Kadambari D; Kumar AS; Revathy M; Anjana R; Adithan C; Dkhar SA
    Environ Toxicol Pharmacol; 2015 Jan; 39(1):102-13. PubMed ID: 25481307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.
    Umamaheswaran G; Dkhar SA; Kalaivani S; Anjana R; Revathy M; Jaharamma M; Shree KM; Kadambari D; Adithan C
    Med Oncol; 2013; 30(3):665. PubMed ID: 23893151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype, allele and haplotype frequencies of four TCL1A gene polymorphisms associated with musculoskeletal toxicity in the South Indian descent.
    Umamaheswaran G; Dkhar SA; Kumar AS; Srinivasa RK; Kadambari D; Adithan C
    Bioimpacts; 2014; 4(2):95-100. PubMed ID: 25035853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
    Umamaheswaran G; Kadambari D; Muthuvel SK; Kumar NAN; Dubashi B; Aibor Dkhar S; Adithan C
    PLoS One; 2021; 16(3):e0247989. PubMed ID: 33760860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association study of aromatase gene (CYP19A1) in essential hypertension.
    Shimodaira M; Nakayama T; Sato N; Saito K; Morita A; Sato I; Takahashi T; Soma M; Izumi Y
    Int J Med Sci; 2008 Feb; 5(1):29-35. PubMed ID: 18274619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic and allelic variability in CYP19A1 among populations of African and European ancestry.
    Starlard-Davenport A; Orloff MS; Dhakal I; Penney RB; Kadlubar SA
    PLoS One; 2015; 10(2):e0117347. PubMed ID: 25647083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of CYP19A1 single-nucleotide polymorphism with digit ratio (2D:4D) in a sample of men and women from Ningxia (China).
    Zhanbing M; Jie D; Chunyue B; Hong L; Liang P; Zhenghao H
    Early Hum Dev; 2019 May; 132():58-65. PubMed ID: 30986648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
    Artigalás O; Vanni T; Hutz MH; Ashton-Prolla P; Schwartz IV
    BMC Med; 2015 Jun; 13():139. PubMed ID: 26067721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population.
    Lee SJ; Kim WY; Choi JY; Lee SS; Shin JG
    J Hum Genet; 2010 Mar; 55(3):189-93. PubMed ID: 20186154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between rs10046, rs1143704, rs767199, rs727479, rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms in aromatase (CYP19A1) gene and Alzheimer's disease risk: a systematic review and meta-analysis involving 11,051 subjects.
    Song Y; Lu Y; Liang Z; Yang Y; Liu X
    Neurol Sci; 2019 Dec; 40(12):2515-2527. PubMed ID: 31278540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up.
    Baatjes K; Peeters A; McCaul M; Conradie MM; Apffelstaedt J; Conradie M; Kotze MJ
    Curr Pharm Des; 2020; 26(46):6007-6012. PubMed ID: 32900345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
    Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
    Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
    Johansson H; Gray KP; Pagani O; Regan MM; Viale G; Aristarco V; Macis D; Puccio A; Roux S; Maibach R; Colleoni M; Rabaglio M; Price KN; Coates AS; Gelber RD; Goldhirsch A; Kammler R; Bonanni B; Walley BA;
    Breast Cancer Res; 2016 Nov; 18(1):110. PubMed ID: 27825388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
    Gervasini G; Jara C; Olier C; Romero N; Martínez R; Carrillo JA
    Br J Clin Pharmacol; 2017 Mar; 83(3):562-571. PubMed ID: 27747906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
    Lunardi G; Piccioli P; Bruzzi P; Notaro R; Lastraioli S; Serra M; Marroni P; Bighin C; Mansutti M; Puglisi F; Porpiglia M; Ponzone R; Bisagni G; Garrone O; Cavazzini G; Clavarezza M; Del Mastro L
    Breast Cancer Res Treat; 2013 Jan; 137(1):167-74. PubMed ID: 23129173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
    Napoli N; Rastelli A; Ma C; Yarramaneni J; Vattikutti S; Moskowitz G; Giri T; Mueller C; Kulkarny V; Qualls C; Ellis M; Armamento-Villareal R
    Bone; 2013 Aug; 55(2):309-14. PubMed ID: 23643682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of CYP19A1 variants and haplotypes on breast cancer risk, clinicopathological features and prognosis.
    Alwan AM; Afzaljavan F; Tavakol Afshari J; Homaei Shandiz F; Barati Bagherabad M; Vahednia E; Kheradmand N; Pasdar A
    Mol Genet Genomic Med; 2021 Jul; 9(7):e1705. PubMed ID: 34014013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP19A1 rs2470152 polymorphism increases susceptibility to depression in Chinese Han population.
    Yang Y; Yan H; Kong Y; Liu L; Peng Q; Wen Y; Zhou Z; Chang Q
    Neurosci Lett; 2019 Nov; 713():134490. PubMed ID: 31518674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
    Ferraldeschi R; Arnedos M; Hadfield KD; A'Hern R; Drury S; Wardley A; Howell A; Evans DG; Roberts SA; Smith I; Newman WG; Dowsett M
    Breast Cancer Res Treat; 2012 Jun; 133(3):1191-8. PubMed ID: 22418701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
    Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
    Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.